Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 vaccine, partnered with GlaxoSmithKline, and is now hoping to have phase 3 data available "by early ...

Medicago has already developed an experimental flu vaccine in Nicotiana benthamian, a plant related to tobacco. When the pandemic struck, the company decided to try to make a COVID-19 vaccine. Now ...

Medicago plant-based vaccine imitates covid-19 spike protein. This latest candidate in the fight against covid-19 works similar to the other vaccines currently available triggering an immune ...

Canadian drug developer Medicago's plant-based COVID-19 vaccine candidate, enhanced by GlaxoSmithKline's booster, was 75.3% effective against the Delta variant of the virus in a late stage study ...

Biotechnology company Medicago now has a facility that needs just 30 days to turn into new flu vaccine the plant that has been the cornerstone of North Carolina’s economy for hundreds of years. ...

Medicago announced Tuesday that its two-dose vaccine was 71% effective at preventing COVID-19 infection in a large, late-stage study that included several variants including the delta variant.

Medicago – a Canadian company with a biomanufacturing facility in Durham – has used it to produce an experimental plant-based vaccine for COVID-19, the coronavirus disease that has now reached ...

Canadian vaccine maker Medicago's COVID-19 vaccine, approved last month in Canada, ... may still want Medicago's shot because of its plant-based technology, ...

Canada's Medicago, a biotech that is using plant technology to manufacture vaccines against Ebola and other viruses, will build a $200 million manufacturing facility in Quebec City. The company is ...

VLP vaccine will be produced using plant leaf production system. Canadian vaccines firm Medicago has been awarded $946,000 in funding from PATH as part of a research collaboration between the ...

Pharmaceutical companies Medicago and GlaxoSmithKline announced Tuesday “positive efficacy and safety results” from a global trial using what they say is the world’s first plant-based ...

Medicago announced Tuesday that its two-dose vaccine was 71% effective at preventing COVID-19 infection in a large, late-stage study that included several variants including the delta variant.